Today I review and link to IDSA Guidelines on the Treatment and Management of Patients with COVID-19 from Infectious Diseases Socity Of America. Published by IDSA, 5/27/2021. Last updated, 8/12/2024
All that follows is from the above resource.
- How to Approach a Patient When Considering Pharmacologic Treatments for COVID-19
- Executive Summary and Background
- Recommendation: Neutralizing Antibodies for Prophylaxis (Pemivibart)
- Recommendation: Nirmatrelvir/Ritonavir
- Recommendation: Molnupiravir
- Recommendation: Remdesivir
- Recommendation: Convalescent Plasma
- Recommendation: Glucocorticoids
- Recommendation: Janus Kinase Inhibitors (Baricitinib and Tofacitinib)
- Recommendation: IL-6 Inhibitors (Tocilizumab and Sarilumab)
- Recommendation: Anakinra
- Recommendation: Hydroxychloroquine and Hydroxychloroquine + Azithromycin
- Recommendation: Hydroxychloroquine as Post-Exposure Prophylaxis
- Neutralizing Antibodies for Treatment
- Recommendation: Lopinavir/Ritonavir
- Recommendation: Inhaled Corticosteroids
- Recommendation: Ivermectin
- Recommendation: Famotidine
- Recommendation: Fluvoxamine
- Recommendation: Colchicine
- Bacterial Co-Infections and Antibiotic Use
- Pediatric Considerations for Treatment of SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children
- Methods and Search Results
- Notes
- Update History
- References
